KPWHRI is taking part in a clinical trial of a nasal COVID-19 vaccine developed by Boost Biopharma Inc.
KPWHRI is recruiting Kaiser Permanente Washington members to take part.
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
Participant in KPWHRI trial receives world’s first-ever injection of investigational SchistoShield vaccination.
NIAID-sponsored study includes Seattle in test for benefits of mixing different vaccine types.
An investigational vaccine developed by Moderna is being tested for safety and immune response in Seattle and 3 other cities.
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
